Ronac Mamtani News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Evolving Use of PARP Inhibitors Requires Biomarker-Driven Approaches to Treatment Selection in Prostate Cancer

Vivek K. Narayan, MD, MS, spotlights 3 case studies of patients with metastatic prostate cancer, delving into the influence of their unique mutational status on treatment decisions, scenarios in which to utilize PARP inhibitor monotherapy vs combination regimens, and key trials that support the use of each approach.

Fox chase cancer centerUnited statesUniversity of pennsylvaniaPooja ghataliaJasone shpilskyVivekk narayanKevin kayvan zarrabiRonac mamtaniSamuel takvorianSidney kimmel cancer center at jefferson healthHospital of the university pennsylvaniaPenn medicineSidney kimmel cancer centerProstate cancer

Maintenance Avelumab Uptake Modest in Advanced Urothelial Carcinoma

The approval and uptake of maintenance avelumab for urothelial carcinoma is associated with upstream firstline treatment selection.

University of pennsylvaniaUnited statesRonac mamtaniFlatiron health

Penn Medicine, Philadelphia: First Mutation-Targeted Bladder Cancer Drug May Be Under-Used | India Education | Latest Education News | Global Educational News

Penn Medicine, Philadelphia: First Mutation-Targeted Bladder Cancer Drug May Be Under-Used | India Education | Latest Education News | Global Educational News
indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.

United statesVivek nimgaonkarRonac mamtaniPenn centerUniversity of pennsylvaniaDrug administrationBiopsy laboratoryPerelman school of medicineAmerican cancer societyPerelman schoolErica carpenterLiquid biopsyFibroblast growth factor receptors

UPenn Researchers Find Low Uptake of Janssen s Balversa in Eligible Bladder Cancer Patients

While low FGFR biomarker testing rates may be contributing to the drug's slow adoption, the analysis found low uptake even among patients who did get tested.

Vivek nimgaonkarJanssen balversaQiagen therascreenRonac mamtaniPenn centerOhio state university comprehensive cancer center jamesTumor material laboratoryDrug administrationUniversity of pennsylvaniaFlatiron healthPrecision medicineErica carpenterCirculating tumor material laboratory

Penn study finds low uptake of first mutation-targeted bladder cancer drug

The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

United statesVivek nimgaonkarRonac mamtaniEmily hendersonPenn centerUniversity of pennsylvaniaDrug administrationBiopsy laboratoryPerelman school of medicineAmerican cancer societyPerelman schoolErica carpenterLiquid biopsyFibroblast growth factor receptorsBladder cancerCancer treatment